';

The history of Eurofins Biomnis

  • 1897

    History

    Marcel Mérieux, a student of Louis Pasteur (Institut Pasteur), establishes Laboratory Marcel Mérieux in Lyon, France, specialising in microbiology.

  • 1937

    History

    Dr. Charles Mérieux takes over his father’s laboratory.

  • 1947

    History

    Charles Mérieux creates the French Institute of Foot-and-mouth Disease amongst the Lyonnaise abattoirs and then the Mérieux Institute.

  • 1982

    History

    A department of Medically Assisted Procreation (MAP), focusing on couple’s infertility is integrated into Laboratory Marcel Mérieux.

  • 1990

    Technology

    First application of the Polymerase Chain Reaction (PCR) technique, discovered at the end of the 80s, for infectious diseases (Virus, bacteria, parasite screening).

  • 1993

    Technology

    Development of PCR technique for application in molecular biology.

  • 1996

    History

    Laboratory Marcel Mérieux acquires the department of specialised pathology from the Institut Pasteur of Lyon

  • 1998

    Technology

    Certification for the screening of Trisomy 21

  • 1999

    History

    Laboratory Marcel Mérieux acquires a well-known specialised pathology lab in Ireland, Claymon Laboratories

  • 2000

    History

    Laboratory Marcel Mérieux acquires Laboratory LCL (Claude Levy), pioneer of radio-immunology in France

  • 2004

    Technology

    Creation of the Genetic Fingerprinting Laboratory whose mission is to establish genetic profiles for the French Justice System.

  • 2008

    History

    Merger of Laboratory Marcel Merieux and Laboratory Claude Levy to form Biomnis, French leader in specialised medical pathology.

  • 2008

    Technology

    Creation of the onco-haematology department, dedicated to the pathologies of malignant haemopathies and solid tumours.

  • 2008

    Technology

    Development of the first therapeutic markers, notably KRAS for colorectal cancer and HER2 for breast cancer.

  • 2013

    Technology

    Biomnis offers new oncology markers: HE4 and Roma score for early diagnosis of ovarian cancer, Septin 9 and [-2] proPSA & Phi index respectively for non-invasive screening of colon and prostate cancers.

  • 2013

    Technology

    Development of NGS technique (New Generation Sequencing) enabling the sequencing of hundreds of thousands of DNA fragments for the diagnosis of genetic diseases.

  • 2014

    Technology

    Biomnis develops an innovative, specialised new test for women via its new screening marker for pre-eclampsia in the 1st trimester of pregnancy.

  • 2014

    Technology

    Application of NGS method to the Non-Invasive Prenatal Testing of trisomies 13, 18 and 21

  • 2014

    Technology

    Mass Spectrometry as chosen method for immunosuppressant drug testing and the therapeutic monitoring of transplanted patients. With over 400 specimens tested per day, Biomnis laboratories is placed n° 1 in Europe for the testing of these immunosuppressants by LC-MS-MS.

  • 2015

    History

    Biomnis Laboratories joins Eurofins Group, global leader of bio-analytical testing.
    eurofins

  • 2015

    Technology

    Performance of new companion diagnostic tests for personalised medicine in oncology, enabling chemotherapy dose adjustment (5-FU).

Eurofins Biomnis uses cookies to offer you the best service. Continuing your navigation, you agree to receive cookies from eurofins-biomnis.com

For more information visit legal notice

Mettez à jour votre navigateur pour consulter ce site